The Keytruda market, valued at $27.80 billion in 2025, is projected to experience steady growth, driven by a compound annual growth rate (CAGR) of 2.94% from 2025 to 2033. This growth is fueled by several key factors. The increasing incidence of cancers like Non-Small Cell Lung Cancer (NSCLC), melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC) significantly contributes to market expansion. Moreover, the rising adoption of Keytruda across various therapeutic approaches—monotherapy, combination therapy, adjuvant, and neoadjuvant—further fuels market expansion. The expansion of hospital and specialty pharmacies, particularly in developed regions like North America and Europe, also enhances accessibility and contributes to market growth. While precise figures for individual segment contributions aren't provided, it is reasonable to expect that NSCLC, given its high prevalence, will maintain a substantial market share. Combination therapies, leveraging Keytruda's efficacy in conjunction with other treatments, are anticipated to witness significant growth due to their enhanced therapeutic outcomes. However, market growth might face certain challenges. Pricing pressures from healthcare providers and payers, the emergence of competing immunotherapies, and the potential for treatment resistance could limit market expansion. Furthermore, geographical variations in healthcare infrastructure and access to advanced therapies could influence the market's regional growth trajectory. While North America currently dominates the market, the Asia-Pacific region, particularly China and India, is expected to witness accelerated growth driven by rising healthcare expenditure and an increasing awareness of advanced cancer therapies. Overall, the Keytruda market demonstrates substantial growth potential, albeit with potential limitations related to pricing, competition, and regional accessibility. Strategic market entry and expansion into high-growth regions, coupled with innovative approaches to address treatment resistance, will be crucial for sustained market success. This comprehensive report provides a detailed analysis of the Keytruda market, encompassing historical data (2019-2024), current estimates (2025), and future forecasts (2025-2033). It delves into various aspects of this crucial oncology therapeutic, providing valuable insights for stakeholders across the pharmaceutical industry. The report leverages high-search-volume keywords like "Keytruda market size," "pembrolizumab market analysis," "Keytruda sales forecast," and "cancer immunotherapy market trends" to ensure optimal search engine visibility. Recent developments include: September 2024: Merck announced that new data from four approved medicines and six pipeline candidates across more than 20 cancer types will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Notably, findings from the Phase 3 KEYNOTE-522 trial in high-risk early-stage triple-negative breast cancer (TNBC), the Phase 3 KEYNOTE-A18 trial in high-risk locally advanced cervical cancer, and the Phase 3 LEAP-012 trial in unresectable, non-metastatic hepatocellular carcinoma (in collaboration with Eisai) have been selected for the prestigious ESMO Presidential Symposium Sessions.September 2024: Astellas Pharma Inc. got approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the combination of PADCEV (enfortumab vedotin) and MSD’s KEYTRUDA (pembrolizumab) for the first-line treatment of adult patients with radically unresectable urothelial carcinoma. This approval, based on the EV-302 trial, showed that the combination therapy nearly doubled median overall survival and significantly extended progression-free survival compared to the current standard of care, platinum-containing chemotherapy. The decision follows a priority review designation by the MHLW, recognizing the clinical usefulness of this novel treatment for a serious disease.. Key drivers for this market are: Rising Prevalence of Cancer, Favourable Regulatory Approvals; Growing Demand for Immunotherapy. Potential restraints include: Rising Prevalence of Cancer, Favourable Regulatory Approvals; Growing Demand for Immunotherapy. Notable trends are: Stomach Cancer Segment is Expected to Witness Significant Growth Over the Forecast Period.

Keytruda is not only Merck & Co.’s top product, but also the best-selling drug worldwide, generating **** billion U.S. dollars in revenue in 2024. The cancer drug with the generic name pembrolizumab increased its revenues by around *** billion U.S. dollars compared to 2023.

The America Cancer Immunotherapy Market Report is Segmented by Therapy Type (Monoclonal Antibodies, Immunomodulators, and More), Cancer Type (Prostate Cancer, Breast Cancer, Lung Cancer, and More), End Users (Hospitals and Clinics, Cancer Research Centers, and More), Route of Administration (Intravenous and More), and Geography (North America and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Keytruda market size is expected to reach $33.77 billion by 2029 at 9.2%, segmented as by melanoma, advanced or unresectable melanoma, adjuvant treatment for melanoma

Keytruda Sales Market Outlook

The Keytruda sales market size is projected to exhibit significant growth globally, with a compound annual growth rate (CAGR) of approximately 12.5% from 2024 to 2032. In 2023, the market size was valued at roughly $18 billion, and it is expected to reach an estimated $52 billion by 2032. This impressive growth can be attributed to several factors, including the increasing prevalence of cancer, advancements in immunotherapy, and expanding approval for Keytruda across various cancer indications. The robust efficacy of Keytruda, a pioneering immune checkpoint inhibitor, continues to drive its adoption as a frontline treatment for multiple cancer types, further solidifying its position in the oncology pharmaceuticals market.

One of the primary growth factors fueling the Keytruda sales market is the rising incidence of cancer worldwide. As the global population ages and lifestyle factors continue to evolve, there has been a notable increase in the prevalence of various cancers. This surge in cancer cases has spurred the demand for effective and innovative treatments, with Keytruda standing out due to its unique mechanism of action as a PD-1 inhibitor. Its ability to enhance the body's immune response to cancer cells has made it a preferred choice among oncologists, leading to its increased usage across multiple cancer indications. Furthermore, ongoing research and clinical trials continue to explore new applications of Keytruda, expanding its therapeutic potential and contributing to market growth.

Another significant factor driving the market growth is the expanding portfolio of indications for which Keytruda is approved. Initially developed for the treatment of melanoma, Keytruda has since received approval for a wide range of cancers, including lung cancer, head and neck cancer, and bladder cancer, among others. This broad approval spectrum has not only increased its adoption among healthcare professionals but has also provided a substantial boost to its sales. Additionally, the increasing acceptance of combination therapies, where Keytruda is used alongside other cancer treatments, has further amplified its market reach and efficacy, making it a cornerstone in modern oncology treatment regimens.

The market growth is also being propelled by advancements in immunotherapy and personalized medicine. Keytruda, as part of the broader category of immune checkpoint inhibitors, has been at the forefront of a revolution in cancer treatment. Its ability to effectively target and modulate the immune system has opened new avenues in the fight against cancer, offering hope for improved patient outcomes. The increasing emphasis on personalized medicine, where treatments are tailored to individual patient profiles, has further enhanced the appeal of Keytruda. By providing a more targeted and efficient treatment option, Keytruda aligns with the modern healthcare focus on precision medicine, thus driving its market demand.

Regionally, North America holds a dominant position in the Keytruda sales market, attributed to the high prevalence of cancer, advanced healthcare infrastructure, and significant investment in research and development. The region's well-established pharmaceutical industry and favorable reimbursement policies also contribute to its leadership in the market. Europe follows closely, with increasing adoption of Keytruda driven by rising cancer awareness and government initiatives supporting cancer treatment. The Asia Pacific region is expected to exhibit the fastest growth rate, driven by the increasing incidence of cancer, growing healthcare expenditure, and expanding access to advanced treatments. Meanwhile, Latin America and the Middle East & Africa are also witnessing gradual growth, albeit at a slower pace, due to improving healthcare systems and rising awareness of immunotherapy benefits.

Indication Analysis

Lung cancer represents one of the most significant indications for Keytruda, and its impact on the market is profound. As lung cancer remains one of the leading causes of cancer-related deaths globally, the demand for effective treatments is paramount. Keytruda has been approved for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), addressing a critical need in oncology care. The robust clinical data supporting its use in these indications has led to its widespread adoption, particularly as a first-line treatment option. The focus on improving survival rates for lung cancer patients has increased the emphasis on immunotherapy, with Keytruda at the forefront, driving significant sales in this segment.

<br /&

The North America Keytruda report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

The global cancer immunotherapy market is set to garner US$ 159.2 billion in revenue in 2024, according to Fact.MR, a market research and intelligence provider. Worldwide demand for cancer immunotherapies is projected to increase at a CAGR of 10% and reach a market value of US$ 412.8 billion by 2034.

Report Attribute	Detail
Cancer Immunotherapy Market Size (2024E)	US$ 159.2 Billion
Forecasted Market Value (2034F)	US$ 412.8 Billion
Global Market Growth Rate (2024 to 2034)	10% CAGR
South Korea Market Value (2034F)	US$ 22 Billion
Cancer Immunotherapy Vaccine Demand Growth (2024 to 2034)	10.1% CAGR
Key Companies Profiled	Eli Lilly and Company; Pfizer, Inc.; Spectrum Pharmaceuticals, Inc.; GlaxoSmithKline Plc.; Amgen Inc.; Bristol-Myers Squibb Company; Janssen Biotech, Inc.; Novartis AG; AstraZeneca Plc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Sanofi; Takeda Pharmaceuticals; Immunocore, Ltd.

Country-wise Analysis

Attribute	United States
Market Value (2024E)	US$ 16.9 Billion
Growth Rate (2024 to 2034)	10.5% CAGR
Projected Value (2034F)	US$ 45.7 Billion

Attribute	Japan
Market Value (2024E)	US$ 10.3 Billion
Growth Rate (2024 to 2034)	10.5% CAGR
Projected Value (2034F)	US$ 28 Billion

Category-wise Analysis

Attribute	Immune Checkpoint Inhibitors
Segment Value (2024E)	US$ 38.5 Billion
Growth Rate (2024 to 2034)	10.1% CAGR
Projected Value (2034F)	US$ 100.7 Billion

Attribute	Cancer Research Centers
Segment Value (2024E)	US$ 43.9 Billion
Growth Rate (2024 to 2034)	10% CAGR
Projected Value (2034F)	US$ 113.9 Billion

The Keytruda market exhibits robust growth, driven by its efficacy in treating various cancers and increasing prevalence of these diseases globally. While precise figures for market size and CAGR are unavailable from the provided text, we can make reasonable estimations based on publicly available data and market trends. Considering the established presence of Keytruda as a leading immunotherapy drug and its consistent performance in clinical trials, a conservative estimate places the 2025 market size at approximately $17 billion USD. This is based on reports indicating billions of dollars in annual sales for Keytruda in recent years. Projecting forward using a moderate CAGR of 8% (a figure reflective of growth in the broader immunotherapy market), we can anticipate continued expansion over the forecast period (2025-2033). This growth will be fueled by ongoing clinical trials exploring new Keytruda applications, expanding patient populations, and continued investment in research and development by Merck. Significant market drivers include the rising incidence of various cancers, an aging global population increasing susceptibility to cancer, and growing awareness and adoption of immunotherapy treatments. Further expansion is expected through the development of combination therapies, utilizing Keytruda in conjunction with other cancer treatments to improve efficacy and overcome resistance. However, potential restraints include high drug costs, potential side effects associated with immunotherapy, and the emergence of competing immunotherapy drugs. The market is segmented by cancer type (lung cancer, melanoma, etc.), treatment setting (first-line, second-line), and geographic region. Merck, as the primary manufacturer, holds a significant market share and actively influences market growth through clinical trials and strategic partnerships. Regional variations in healthcare infrastructure and reimbursement policies will undoubtedly affect market penetration. Overall, the long-term prognosis for the Keytruda market remains positive due to its ongoing success and the continuously evolving landscape of cancer treatment.

Global Cancer Immunotherapy Market size is expected to be worth around US$ 691.0 Billion by 2034 from US$ 226.5 Billion in 2024.

In 2024, half of Merck & Co.’s total revenue was generated from the company’s domestic market in the United States. Sales revenue in the Asia Pacific region, when including China and Japan, stood at **** billion U.S. dollars. Emerging markets: the risks and rewards Merck’s business operations in China fluctuated recently. However, investment in emerging markets can come with an element of risk due to the financial instability of domestic economies: companies may face barriers in the form of trade restrictions or pricing controls, for example. A failure to operate in these markets could negatively impact the future of the business, but there are no guarantees that efforts to expand will succeed. Why are drug patents important? The cancer-fighting drug Keytruda was Merck’s top-selling product in 2024, generating sales revenue of approximately ** billion U.S. dollars. Around ** percent of the Keytruda sales were generated in the United States, where the product has key patent protection until 2028. Patents can cover the marketing of a product, but also its pharmaceutical formulations and the processes involved in its manufacture. The expiration of a patent normally results in significant competition from generic versions, which can quickly impact the revenues of a product.

Global Keytruda Market Analysis The global Keytruda market is expected to exhibit a substantial compound annual growth rate (CAGR) over the forecast period 2025-2033, reaching a valuation of several billion USD by 2033. The market expansion is primarily driven by the increasing prevalence of cancer, rising adoption of immunotherapy for cancer treatment, and the growing demand for precision medicine. Additionally, ongoing clinical trials and the development of new Keytruda-based combination therapies are anticipated to further fuel market growth. Competitive Landscape and Regional Dynamics Merck & Co. Inc. is the dominant player in the global Keytruda market, with a significant share. Other notable companies operating in this space include Bristol-Myers Squibb, Roche, and AstraZeneca. Regional analysis reveals that North America holds the largest market share due to the high incidence of cancer and the well-established healthcare infrastructure in the United States. Europe is also a key market, followed by Asia Pacific, which is expected to experience substantial growth over the forecast period owing to the rapidly aging population and increasing healthcare expenditure in the region.

Snapshot img

Immunotherapy Drugs Market Size 2024-2028

The Global Immunotherapy Drugs Market size is estimated to grow by USD 111.35 billion, at a CAGR of 11.31% between 2023 and 2028. The increasing prevalence of cancer, driven by factors such as aging populations and lifestyle changes, is leading to a greater demand for cancer treatments and therapies. Growing investments in pharmaceutical technology, such as advancements in drug delivery systems and personalized medicine, are driving innovation in the industry and creating new opportunities for growth. Increasing awareness in patients, fueled by initiatives from healthcare organizations and advocacy groups, is leading to earlier detection and treatment of diseases, further driving market growth.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by End-user, Type and Geography Analysis

By End-user

The hospitals segment is estimated to witness significant growth during the forecast period. This segment plays an important role in the provision of health care services. Hospitals are the first point of entry for diagnosing, treating, and managing a wide range of diseases. In addition, they provide access to specialists and cutting-edge medical facilities. Furthermore, with the growing acceptance of immunotherapy as an innovative treatment, hospitals have become an essential part of the global market.

Get a glance at the market contribution of various segments Download PDF Sample

The hospitals segment was the largest segment and was valued at USD 56.54 billion in 2018. Moreover, these work by stimulating an individual's immune system to recognize and kill cancer cells, providing a more targeted and potentially more successful treatment. In addition, hospitals are leading the way in adding this to their treatment plans, making sure patients get the best care possible. Furthermore, they support clinical trials, research, and development efforts which is fuelling the growth of this segment which in turn drives the immunotherapy drug market growth.

By Type

The presence of the monoclonal antibodies segment has fuelled the growth of the global market. In addition, these antibodies, which are created in laboratories, are designed to bind to and target specific proteins that are present in cancer cells and immune cells. In addition, this selective approach has enabled them to be highly effective in the treatment of a variety of cancers and autoimmune diseases. Furthermore, the monoclonal antibody drug development and approval have seen a dramatic increase in recent years, reflecting the growing prevalence and efficacy of this therapy. Cancer biologics, including advanced immunotherapy drugs, are revolutionizing the treatment landscape by targeting specific cancer cells and enhancing the body’s immune response to fight tumors more effectively. Hence, such factors are fuelling the growth of this segment which in turn will drive the market during the forecast period.

By Region

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are fuelling the growth of the market in North America include the increasing prevalence of various types of diseases and allergies such as cancer and tuberculosis in the region. In addition, food allergies contribute to a high share of the investments in the immunotherapy market in the region. For example, according to 2021 data from Food Allergy Research and Education (FARE), 32 million people in the US suffer from food allergies. Each year, 200,000 people in the US require emergency medical care due to food allergies. Furthermore, besides allergies, cancer contributes to a large part of the investment of research. Hence, such factors are driving the market in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape

Immunotherapy drugs have emerged as a promising avenue for treating a wide array of diseases. Target diseases encompass autoimmune and inflammatory diseases, infectious diseases, and chronic illnesses, driving research collaborations and advancements in biotechnology. Biosimilars offer cost-effective alternatives, particularly in the biopharmaceutical industry, where targeted therapies like interferons and interleukins are gaining traction. With supportive government policies, the focus on immunotherapy extends to segments like autoimmune diseases and vaccines segment, addressing critical areas such as organ failure and cancer, including HER2-positive breast cancer and lung cancer. Immunotherapy drugs are increasingly

The U.S. Cancer Immunotherapy market is projected to be valued at $xx billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of xx%, reaching approximately $xx billion by 2034.

The North American cancer therapy market, encompassing the United States, Canada, and Mexico, is experiencing robust growth, projected to maintain a Compound Annual Growth Rate (CAGR) of 8.10% from 2025 to 2033. This expansion is fueled by several key factors. Firstly, the increasing prevalence of various cancer types, particularly blood cancers, breast cancer, and prostate cancer, is driving demand for advanced therapies. Secondly, significant advancements in cancer treatment modalities, such as targeted therapy, immunotherapy, and hormonal therapy, alongside improvements in early detection and diagnosis, are contributing to market growth. The aging population within North America further exacerbates the demand, as older individuals are more susceptible to various cancers. Finally, substantial investments in research and development by pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck & Co., are continuously expanding the therapeutic options available. The market is segmented by treatment type (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, others), cancer type (blood, breast, prostate, gastrointestinal, gynecologic, respiratory/lung, others), and end-user (hospitals, specialty clinics, cancer centers). Despite the positive growth trajectory, certain challenges exist. High treatment costs remain a significant barrier to access, particularly for certain patient populations. Regulatory hurdles in securing approvals for new drugs and therapies can also delay market entry and limit immediate growth potential. Furthermore, the potential for drug resistance and the need for personalized medicine strategies present ongoing challenges for the industry. However, ongoing innovation in targeted therapies and personalized medicine approaches are mitigating these restraints and should contribute to sustained growth in the coming years. The major players are continually innovating to address these challenges and tap into the expanding market share. The US market is expected to dominate due to its advanced healthcare infrastructure and higher per capita expenditure on healthcare. Canada and Mexico will exhibit steady growth, albeit at a potentially slower pace, reflecting their distinct healthcare systems and market dynamics. Recent developments include: In September 2022, Eli Lilly and Company announced that the United States Food and Drug Administration (FDA) has approved Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options., In August 2022, the United States Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.. Key drivers for this market are: Rising Prevalence of Cancer, Strong R&D Initiatives from Key Players and the Government; Growing Government Initiatives for Cancer Awareness. Potential restraints include: Rising Prevalence of Cancer, Strong R&D Initiatives from Key Players and the Government; Growing Government Initiatives for Cancer Awareness. Notable trends are: The Target Therapy Segment is Expected to show the Fastest Growth During the Forecast Period.

The Pembrolizumab market, while experiencing robust growth, faces complexities inherent to the oncology drug landscape. Let's assume a 2025 market size of $15 billion, reflecting the substantial revenue generated by this leading immunotherapy. A conservative Compound Annual Growth Rate (CAGR) of 8% from 2025-2033 is projected, driven primarily by increasing cancer incidence globally, particularly lung cancer and melanoma, the key indications for Pembrolizumab. Expanding approvals for new cancer types and improved understanding of its efficacy in combination therapies further fuel market expansion. However, the market's growth isn't without its challenges. High drug prices and the emergence of biosimilar competitors pose significant restraints. Patent expirations in various regions will also introduce pricing pressures and increased competition within the next decade. Segmentation within the market is significant, with variations based on treatment line (first-line vs. later lines), cancer type, and geographical region. Data suggests North America currently holds the largest market share, followed by Europe, driven by advanced healthcare infrastructure and higher adoption rates. Merck's dominance in the market, as the originator of Pembrolizumab (Keytruda), is expected to continue, although strategic partnerships and competition from other immunotherapies are expected to gradually influence market share. The forecast period (2025-2033) will witness a dynamic interplay of factors influencing Pembrolizumab’s market trajectory. While the high CAGR reflects significant growth opportunities, the market faces headwinds from pricing pressures and competitive entrants. Continued investment in research and development of combination therapies and exploration of new indications will be crucial for sustained market growth. Regional variations in healthcare access and reimbursement policies will also dictate market penetration. Understanding these diverse factors, including emerging clinical trial data, regulatory landscape changes, and shifts in treatment paradigms, is crucial for accurately predicting future market performance. A keen eye on competitor activity and biosimilar development will also be imperative for stakeholders navigating this complex landscape.

The North America Immunotherapy Drugs report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

The America Cancer Immunotherapy market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

Snapshot img

Cancer Immunotherapy Market Size 2024-2028

The cancer immunotherapy market size is forecast to increase by USD 45.5 billion at a CAGR of 8.1% between 2023 and 2028. The market is witnessing substantial growth due to the high prevalence of cancer, increasing consumer awareness towards advanced treatment options, and a robust Research and Development (R&D) pipeline focusing on monoclonal antibodies. This expansion is primarily driven by the demand for innovative solutions, advancements in technology, and evolving consumer preferences. As the industry evolves, there is a transition towards more efficient systems, improved accessibility, and higher industry standards. Companies in this sector are adapting their strategies to align with these trends, prioritizing sustainability and operational efficiency to maintain a competitive edge. The market's future direction is influenced by these factors, ensuring long-term growth and expansion. The growing demand for advanced cancer treatment solutions continues to fuel market evolution, with a focus on delivering effective, accessible, and cost-efficient therapies.

What will be the size of the market during the forecast period?

Request Free Sample

Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Type

  Monoclonal antibodies
  Check point inhibitors and immunomodulators
  Cancer vaccines


Application

  Lung cancer
  Breast cancer
  Colorectal cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    France


  Asia

    China


  Rest of World (ROW)

Which is the largest segment driving market growth?

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period.

Monoclonal antibodies and checkpoint inhibitors have emerged as key players In the cancer treatment landscape. These man-made proteins, designed to mimic the immune system's response, are used to target specific cancer cells, such as those expressing human epidermal growth factor receptor 2 in breast cancer, treated with trastuzumab. Lung, colorectal, melanoma, breast, head & neck, and prostate cancers are among the many types treated with these agents. Hospitals, clinics, and cancer research centers administer these therapies, which include cancer vaccines, immunomodulators, target therapies, and traditional chemotherapies or radiation therapy. Immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have revolutionized cancer treatment, offering improved patient outcomes.

Financial burden remains a concern, with new treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors under development. Bioinformatics tools aid In the discovery and development of these therapies. Oncolytic viral therapies, such as talimogene laherparepvec and sipuleucel-T, and repotrectinib, a selective TRK inhibitor, are also gaining popularity. The healthcare industry, including hospital pharmacies and online pharmacies, plays a crucial role In the distribution and administration of these treatments.

Get a glance at the market share of various regions. Download the PDF Sample

The Monoclonal antibodies segment was valued at USD 36.30 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 43% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The North American region leads The market due to substantial investments In the oncology sector, particularly In the US. With a significant presence of pharmaceutical companies, the US dominates the regional market and contributes significantly to its global share. In the US, cancer is a prevalent chronic disease, with approximately 436 new cases reported per 100,000 population and 156 deaths In the same year. Immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and cancer vaccines, are increasingly used for treating various types of cancer, such as lung, breast, colorectal, melanoma, head & neck, prostate, and others. Hospitals, clinics, and cancer research centers are key end-users of these therapies.

Immunomodulators, target therapies, traditional chemotherapies, and radiation therapies are also used in combination with immunotherapies. Financial burden remains a challenge for cancer patients, with treatments like quizartinib for acute myeloid leukemia and FLT3 inhibitors requiring significant investment. Innovations

Keytruda is projected to stay the top-ranked drug worldwide based on sales in 2025, with some 31 billion U.S. dollars. This statistic displays the expected top drugs in 2025 based on sales projections as of December 2024. It has to be mentioned that Novo Nordisk's brands Ozempic and Wegovy are, in fact, the same drug (generic name semaglutide), where only dosage and dose form define if it is used for diabetes or weight loss. It is very similar in the case of Eli Lilly's Mounjaro and Zepbound which are basically one and the same drug (generic name tirzepatide). Oncology's dominance in pharmaceutical revenues Cancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2025 underscore this trend, while the drug's revenue increased by more than four billion dollars between 2023 and 2024. This growth is part of a larger pattern in global oncology spending, which exceeded 250 billion U.S. dollars globally in 2024, almost doubling from five years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030. Market dynamics and company performance Merck & Co. has seen its overall revenue increase to 64 billion in 2024, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, dropped out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

PD-1 inhibitors occupy a significant market share due to their versatility and effectiveness in treating multiple cancer types. Key products in this segment include Keytruda, Opdivo, and Tecentriq. CTLA-4 inhibitors also have a strong market presence, with Yervoy being a leading product. These products have received regulatory approvals for various cancer indications and are widely used in clinical settings. Recent developments include: November 2023:Merck & Co., Inc., received US Food and Drug Administration (FDA) approval for KEYTRUDA, anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line antidote of adults with locally cutting-edge unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Notable trends are: Expanding product approvals by the regulatory authorities is driving the market growth..